Sign In
Buy GRPH
$0.0001
+0 (+0%)
At Close: Apr 18, 2019
Graphite Bio Declares Special Dividend In Connection with Proposed Merger with Lenz Therapeutics
05:00pm, Friday, 08'th Mar 2024
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)---- $GRPH #GraphiteBio--Graphite Bio, Inc. (Nasdaq: GRPH) (“Graphite” or the “Company”) today announced that its Board of Directors has declared a
NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed merger of Graphite B
NEW ORLEANS , Jan. 26, 2024 /PRNewswire/ -- Former Attorney General of Louisiana Charles C. Foti, Jr., Esq.
NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed merger of Graphite B
Shareholder Alert: Ademi LLP investigates whether Graphite Bio, Inc. has obtained a Fair Price in its transaction with LENZ Therapeutics
02:08pm, Thursday, 16'th Nov 2023
MILWAUKEE , Nov. 16, 2023 /PRNewswire/ -- Ademi LLP is investigating Graphite Bio (NASDAQ: GRPH) for possible breaches of fiduciary duty and other violations of law in its transaction with LENZ Therap
What Makes Graphite Bio, Inc. (GRPH) a New Buy Stock
01:32pm, Thursday, 16'th Nov 2023
Graphite Bio, Inc. (GRPH) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
GRPH Stock Alert: Halper Sadeh LLC Is Investigating Whether the Merger of Graphite Bio, Inc. Is Fair to Shareholders
08:38am, Wednesday, 15'th Nov 2023
NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLC, an investor rights law firm, is investigating whether the merger of Graphite Bio, Inc. (NASDAQ: GRPH) and LENZ Therapeutics is fair to Graphite shareholder
LENZ Therapeutics and Graphite Bio Announce Merger Agreement
07:00am, Wednesday, 15'th Nov 2023
SAN DIEGO & SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--LENZ Therapeutics, a late-stage biopharmaceutical company focused on developing and commercializing innovative therapies to improve vision, an
Graphite Bio Reports Recent Business Progress and Fourth Quarter and Fiscal Year 2022 Financial Results
04:05pm, Monday, 20'th Mar 2023
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Graphite Bio, Inc. (Nasdaq: GRPH) today reported recent business progress and fourth quarter and fiscal year 2022 financial results. “As announced last
Hundreds more tech, biotech layoffs hit Bay Area, Google real estate ally cuts jobs
02:08pm, Monday, 13'th Mar 2023
About 600 more tech and biotech layoffs rocked the Bay Area job market in a fresh round of cutbacks that suggest the staffing reductions in the region have yet to run their course, new state governmen
Graphite Bio Announces Process to Explore Strategic Alternatives and Corporate Restructuring
04:05pm, Wednesday, 22'nd Feb 2023
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Graphite Bio, Inc. (Nasdaq: GRPH) today announced that it has completed a review of its business, including the status of its programs, resources and capa
Down -39.59% in 4 Weeks, Here's Why Graphite Bio, Inc. (GRPH) Looks Ripe for a Turnaround
11:17am, Tuesday, 10'th Jan 2023
Graphite Bio, Inc. (GRPH) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings
Top 5 Health Care Stocks That May Surge - Graphite Bio (NASDAQ:GRPH), Fate Therapeutics (NASDAQ:FATE)
07:33am, Tuesday, 10'th Jan 2023
The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies.
Graphite Bio Announces Voluntary Pause of Phase 1/2 CEDAR Study of nulabeglogene autogedtemcel (nula-cel) for Sickle Cell Disease
04:05pm, Thursday, 05'th Jan 2023
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Graphite Bio, Inc. (Nasdaq: GRPH) today announced it is voluntarily pausing the Phase 1/2 CEDAR study of nulabeglogene autogedtemcel (nula-cel) for sickle
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Graphite Bio, Inc. (Nasdaq: GRPH), a clinical-stage, next-generation gene editing company harnessing the power of high-efficiency precision gene repair to
